AstraZeneca invests USD 2.00 billion and AstraZeneca stock costs EUR 141.25

Published on 10/02/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 6.00 percent to USD 30.70 billion. AstraZeneca stock costs EUR 141.25 on October 2, 2026 versus EUR 140.40.

Isometrische 3D-Grafik zeigt Labor, Produktion und Pharma-Logistikkette — AstraZeneca plc (ISIN GB0009895292) steuert eine komplexe Wertschöpfungskette von Forschung bis zur globalen Arzneimittel-Distribution, Illustration mit AI erstellt.

AstraZeneca invested USD 2.00 billion in Summit Therapeutics on September 29, 2026, securing access to the cancer drug ivonescimab. AstraZeneca stock was trading at EUR 141.25 at Lang & Schwarz on October 2, 2026, up 0.61 percent versus the prior close of EUR 140.40.

Summit deal expands oncology options

As IG reported on September 29, 2026, the investment gives AstraZeneca rights equivalent to 12.00 percent of Summit's outstanding common stock, or 10.60 percent on a fully diluted basis. The companies also plan clinical trials combining ivonescimab with AstraZeneca's antibody-drug conjugate sonesitatug vedotin.

The structure limits the immediate commitment to a strategic investment rather than a full acquisition. The next external milestone is a November 14, 2026, FDA decision for ivonescimab in a lung-cancer setting, according to the same IG report.

First-half growth supports the strategy

AstraZeneca generated USD 30.70 billion of revenue in the first half of 2026, up 6.00 percent year over year, while core operating profit increased 11.00 percent, according to IG. Oncology accounted for 46.00 percent of first-half revenue and produced USD 14.10 billion of sales, up 15.00 percent at constant exchange rates.

In its first-half 2026 earnings call, SquawkNews reported that core earnings per share grew 11.00 percent. Management reiterated full-year guidance for total revenue growth in the mid- to high-single-digit percentage range and core earnings per share growth in the low double-digit percentage range.

Analysts keep a mixed risk profile

MarketBeat reported on September 29, 2026, that Deutsche Bank reaffirmed a Hold rating with a GBP 117.00 price objective. The same report listed 14 Buy, 3 Hold and 1 Sell ratings among 18 firms, with an average target of GBP 150.00.

The contrast is clear: AstraZeneca's recent operating figures show double-digit growth in core earnings per share and oncology, while the Summit investment adds clinical and regulatory exposure. For investors, the value of the deal depends on whether ivonescimab can expand beyond a single approval into a broader oncology platform.

Stock trades in the London session

AstraZeneca's primary listing is on the London Stock Exchange. The stock was last at GBp 12,020.00 on October 2, 2026 at 12:40 p.m. BST during the open session, against a 52-week range of GBp 9,892.00 to GBp 15,732.00. Market capitalization stood at GBP 186.4 billion on October 2, 2026.

The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.